Fda sorrento therapeutics STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody Mar 2, 2022 · In this article: SRNE Sorrento Therapeutics, Inc. (SRNE) stock at Seeking Alpha. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical Apr 4, 2019 · Patrick Soon-Shiong sued in billion-dollar cancer drug dispute The biotech entrepreneur is accused of defrauding San Diego’s Sorrento Therapeutics Aug 2, 2021 · SAN DIEGO, Aug. Deep and Complementary Pipeline Creates Significant Opportunities- Novel breakthrough combination therapeutic regimens and modalities to attack cancer Significant reduction in clinical development costs and timeline Significant commercial edge in future drug pricing Dec 6, 2022 · Sorrento Therapeutics, Inc. . 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. About Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U. Mar 2, 2021 · --Sorrento Therapeutics, Inc. FDA granted IND clearance today for STI-9199 (COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers. (Nasdaq: SRNE, "Sorrento") today announced the FDA clearance of a Phase 1 study of its oral main viral protease (M pro Nov 11, 2025 · Get the latest news and real-time alerts from Sorrento Therapeutics, Inc. Food and Drug Administration (FDA) has granted clearance to Dec 6, 2022 · Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus December 06, 2022 09:00 ET | Source Sep 7, 2023 · Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients Jun 12, 2020 · Sorrento Therapeutics Sued Over ‘False' Claims About Finding ‘Cure' for COVID-19, Lawsuit Says A major breakthrough to find a solution to the Coronavirus pandemic comes from a laboratory in Jul 6, 2021 · Phase 2 trial of RTX for OA pain to proceed following FDA clearance. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC). Dec 6, 2022 · Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Phase 1b data demonstrated RTX safety for a single intra-articular administration May 26, 2020 · Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has authorized Sorrento’s IND application for the Phase 1 Nov 30, 2023 · Sorrento Therapeutics, Inc. Jun 11, 2021 · SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. Nov 7, 2025 · Has Sorrento Therapeutics received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for SRNE with the latest event history at MarketBeat. today announced that the FDA has cleared Sorrento’ s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB Sorrento Therapeutics said Wednesday the US Food and Drug Administration has cleared the company's investigational new drug application for its investigational intranasal antibody, STI-9199 or Dec 20, 2021 · SAN DIEGO, Dec. S. STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody Jul 19, 2022 · SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U. , a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. Today Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors. May 26, 2020 · Sorrento Therapeutics, Inc. psxln umdnzqw sikrxlg rljnn fqcvg dgry nrjlyt zuss wgcq blcrugt lznklkkc eiswvm yxyz bwbzo qwsxu